Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance.

Abstract: The invention relates to developing a novel water and capsule formulation using fenofibrate which is difficult to dissolve and control its release rate in vitro. For example, the invention relates to the creation of capsules and wafers comprising: fenofibrate, a surfactant, a carrier wax, a film former, a plasticizer, and optionally a super disintegrant or other ingredients. The invention further relates to the process of forming such capsules and wafers.

Abstract: The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device.

Abstract: The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound that includes: a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, one or more dicarboxylic acids, 0.5 to 10.0 wt.-% (based on the total weight of the composition) of one or more monocarboxylic acids, and water or an aqueous solvent mixture. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.

Abstract: The invention relates to an apparatus comprising a separating tool and comprising a counterpressure plate for producing contour geometries in adhesive-containing composite materials, wherein the separating tool can be moved in translational tool stroke directions between an inoperative position and a parting position normal to the counterpressure plate, and also to a method for producing contour geometries in adhesive-containing composite materials by means of an apparatus of this kind. The separating tool and the counterpressure plate can be actuated relative to one another by means of at least one actuator in at least one excitation direction with a ramp function and/or with a jump function. Each of these excitation directions lies in a parallel plane to a cutting edge plane of the separating tool. The present invention permits reliable separation of a stamped grid from laminate sections which remain on a carrier film.

Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase comprises the additive and an active agent dissolved therein, the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate proportional to the amount of active agent in the biphasic layer.

Abstract: The invention relates to a transdermal therapeutic system (TTS) for delivering pharmaceutical active ingredients. The TTS includes a cover layer and at least one active-ingredient-containing carrier material. At least one retaining element is located between the active-ingredient-containing carrier material and the cover layer, with the retaining element fixing the active-ingredient-containing carrier material onto the cover layer. The invention further relates to a method for fastening an active-ingredient-containing carrier material to a cover layer of a TTS in the presence of hook-and-loop strip segments and the use of a hook-and-loop strip in transdermal or iontophoretic administration of pharmaceutical or therapeutic active ingredients to patients.

Abstract: The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.

Abstract: A transparent or translucent medical active substance patch is provided that includes a matrix of monolayer or multilayer configuration with at least one active substance-containing layer contained therein and a backing layer connected with the matrix. The patch, having been applied to the skin of a first person, has a lightness color value L1 at a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness color value L2, with L2 being the lightness value of the region of skin of the same person which surrounds the applied patch, with the same being true of the skin of a second or any other person, provided that for all the persons mentioned, the L2 of their respective skin is in the range from 5° to 100°, especially in the range from 20° to 90°.

Abstract: The invention relates to a process for preparing an active-principle-containing adhesive formulation for use in a transdermal therapeutic system, comprising the following steps: a) providing an adhesive formulation containing a carboxylic acid ester-based solvent and a self-adhesive polymer matrix containing monomers of the compounds on which the polymer matrix is based, b) removing the carboxylic acid ester-based solvent and the monomers from the adhesive formulation, c) re-dissolving the compound obtained in step b) in an organic solvent that does not contain any ester groups, and adding a pharmacologically active principle having at least one hydroxyl group, carboxyl group, amino group and/or ester group so that the active-principle-containing adhesive formulation is obtained. The invention also relates to a transdermal therapeutic system containing the active-principle-containing adhesive formulation.

Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.

Abstract: The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention.

Abstract: The present invention relates to a microneedle system (MNS) for intradermally delivering solutions or formulations. The invention relates to a microneedle system, comprising a cover element (1), an active substance container (2), a frame (3), a microneedle array (MNA) (4) and a base plate (5), wherein the microneedle array (MNA) (4) is connected to the frame (3), and the base plate (5) has an opening for receiving the microneedle array (4), the cover element (1) and the base plate (5) are movably connected to one another, the base plate (5) is joined to a surgical tape (6), and the frame (3) and the base plate (5) can be linearly displaced with respect to one another. The MNS according to the invention is suitable for intradermally administering medicinal drugs, active substances, pharmaceutical or cosmetic compositions or other substances to an individual, and preferably to a patient, over an extended period.

Abstract: The invention relates to a microneedle array and to the use thereof for intradermal delivery, comprising a plurality of microneedles on a carrier, wherein this microneedle array is suitable for penetrating the skin of humans or animals and includes at least one color change indicator.

Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure comprising a therapeutically effective amount of asenapine, said self-adhesive layer structure comprising: A) a backing layer; B) an asenapine-containing layer comprising: 1. asenapine in the form of the free base; and 2. a polymer selected from the group consisting of polysiloxanes and polyisobutylenes in an amount of more than 50% by weight based on the total weight of the asenapine-containing layer; and C) optionally an additional skin contact layer.

Abstract: The present invention relates to a transdermal therapeutic system formed from (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, in which the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer; a kit containing two transdermal therapeutic systems of the present invention; and methods for the preparation of the transdermal therapeutic system of the present invention. The present invention further relates to methods of treatment based upon the application of the inventive transdermal therapeutic systems once or twice weekly via systems adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.

Abstract: A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.

Abstract: The present application relates to a transdermal therapeutic system comprising a backing layer impermeable to active substances and a polymer matrix on one side of the backing layer impermeable to active substances, wherein the polymer matrix comprises at least one pharmaceutically active substance, at least one inherently non-self-adhesive polymer and at least one plasticizer, said polymer matrix being free of adhesive polymers. The invention further relates to a method of producing the transdermal therapeutic system and to the use thereof as a drug.

Abstract: The invention relates to a transdermal therapeutic system that includes a) a backing layer which faces away from the skin, is impermeable to the active substance, and is equipped with an adhesive layer for fixing onto the skin, b) an active substance reservoir which contains at least one active substance, c) a barrier layer which faces the skin, adjoins the active substance reservoir, is impermeable to the active substance and has at least one opening, and d) a removable protective layer, in which the backing layer which is equipped with the adhesive layer projects beyond the barrier layer on all sides.

Abstract: Adhesive bandages are provided with a water-vapor permeable back layer and an adhesive layer, in which the adhesive layer includes 10 weight percent of a disperse internal phase of hydrophilic particles that are water-swellable in an outer phase that includes at least 10 weight percent of a styrene block copolymer and at least 20 weight percent of an ester resin of colophony, and that can further contain at least one anti-virus substance.